WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Boehringer Ingelheim

Boehringer IngelheimThe Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative "Making more Health" and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales.

www.boehringer-ingelheim.com

Boehringer Ingelheim RSS Channel

Filters
List of articles in category Boehringer Ingelheim
Title Published Date
€1 Million Awarded to Winning Projects 30 August 2011
Boehringer Ingelheim licenses ProBioGen's novel GlymaxX® technology 19 August 2011
Boehringer Ingelheim and Ashoka's Changemakers Launch "Making More Health" Competition 11 July 2011
Boehringer Ingelheim and Ashoka announce a global partnership for "Making More Health" 23 June 2011
FDA approves linagliptin tablets for the treatment of type 2 diabetes 05 May 2011
Boehringer Ingelheim maintains sales level/course set for the future: product pipeline well-filled 12 April 2011
Boehringer Ingelheim's lead hepatitis C compound moves into phase III 04 April 2011
MorphoSys Signs Manufacturing Agreement with Boehringer Ingelheim 16 March 2011
Pfēnex Inc. and Boehringer Ingelheim Announce Non-Exclusive Strategic Agreement 15 February 2011
Elan and Boehringer Ingelheim Announce Development and Manufacturing Agreement 13 February 2011
Boehringer Ingelheim and Eli Lilly and Company Announce Strategic Alliance 16 January 2011
LUX-Lung 1 trial suggests benefit from afatinib* in lung cancer patients 09 December 2010
Boehringer Ingelheim steps up to the challenge in support of World Diabetes Day 16 November 2010
Collaboration of Boehringer Ingelheim and VTU Technology 11 November 2010
US FDA Approves Pradaxa® (dabigatran etexilate) 22 October 2010
Afatinib (BIBW 2992) triples progression free survival in phase III study in lung cancer patients 12 October 2010
Boehringer Ingelheim Initiates Phase III Clinical Trial with Novel Oral Agent in Advanced Breast Cancer 20 September 2010
Boehringer Ingelheim inaugurates the Shanghai "Center of Competence" 27 August 2010
Boehringer Ingelheim affirms safety of telmisartan with an analysis of 50,000 patients 15 June 2010
New study results on Dulcolax® confirm efficacy and safety 13 May 2010
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • Next
  • End

Business & Industry

  • GSK completes acquisition of Sierra Oncology
  • Pfizer and BioNTech announce new agreement with U.S. government to provide additional doses of COVID-19 vaccine
  • Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology
  • New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta® (ofatumumab) had no evidence of disease activity (NEDA-3)
  • Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against Omicron

Research & Development

  • Inhalable COVID-19 vaccine shows promise in rodent model
  • Researchers discover new leukemia-killing compounds
  • Oral antiviral drug effective against respiratory syncytial virus (RSV) identified by researchers
  • Biomarkers found that could be drug targets against a deadly form of brain cancer
  • COVID-19 rebound after taking Paxlovid likely due to insufficient drug exposure
  • Novel drug combo activates natural killer cell immunity to destroy cancer cells
  • Broadly neutralizing antibodies could provide immunity against SARS-CoV-2 variants

Conferences & Events

  • New approach to treatment of deadly kidney cancer
  • SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
  • Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
  • SMi's 22nd Annual Pain Therapeutics Conference
  • SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
  • SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
  • SMi's 3rd Annual AI in Drug Discovery Conference

Regulatory Affairs

  • FDA approves first systemic treatment for alopecia areata
  • FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
  • FDA limits use of Janssen COVID-19 vaccine to certain individuals
  • EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice
  • FDA approves first generic of Symbicort to treat asthma and COPD
  1. You are here:  
  2. Home
  3. Boehringer Ingelheim

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2022. All Rights Reserved.